Argenx Announces Positive Topline Results From Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Argenx's Vyvgart Scored Another Win — Why Shares Bolted

Argenx stock surged Monday after its blockbuster autoimmune drug, Vyvgart, showed promise in patients with inflammatory diseases.

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM

Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis

Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug